[1]陈甜甜,潘跃银,沈夏波.新辅助内分泌治疗与新辅助化疗用于乳腺癌中的短期疗效Meta分析[J].医学信息,2020,33(14):67-71，75.[doi:10.3969/j.issn.1006-1959.2020.14.020]
　CHEN Tian-tian,PAN Yue-yin,SHEN Xia-bo.Meta-analysis of Short-term Efficacy of Neoadjuvant Endocrine Therapy and Neoadjuvant Chemotherapy in Breast Cancer[J].Medical Information,2020,33(14):67-71，75.[doi:10.3969/j.issn.1006-1959.2020.14.020]
点击复制

新辅助内分泌治疗与新辅助化疗用于乳腺癌中的短期疗效Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年14期
页码:
67-71，75
栏目:
论著
出版日期:
2020-07-15

文章信息/Info

Title:
Meta-analysis of Short-term Efficacy of Neoadjuvant Endocrine Therapy and Neoadjuvant Chemotherapy in Breast Cancer
文章编号:
1006-1959（2020）14-0067-06
作者:
陈甜甜; 潘跃银; 沈夏波
（1.安徽医科大学第一附属医院肿瘤科，安徽 合肥 230022；2.安徽省立医院肿瘤科，安徽 合肥 230001）
Author(s):
CHEN Tian-tian; PAN Yue-yin; SHEN Xia-bo
(1.Department of Oncology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,Anhui,China;2.Department of Oncology,Anhui Provincial Hospital,Hefei 230001,Anhui,China)
关键词:
乳腺癌; 新辅助内分泌治疗; 新辅助化疗
Keywords:
Breast cancer; Neoadjuvant endocrine therapy; Neoadjuvant chemotherapy
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2020.14.020
文献标志码:
A
摘要:
目的 对新辅助内分泌治疗和新辅助化疗在乳腺癌治疗中的短期疗效进行系统评价，以期为临床诊疗工作中新辅助治疗方式的选择提供参考。方法 通过检索中国知网、万方、维普、中国期刊网全文数据库和Cochrane Library、PubMed、EMBASE、Web of Science等数据库，检索出直接比较新辅助内分泌治疗和新辅助化疗短期疗效的文献，采用RevMan 5.3作为数据分析工具进行Meta分析，比较两种方法的肿瘤缓解率（RR）、临床完全缓解率（cCR）、病理完全缓解率（pCR）和保乳率（BCS）。结果 最后纳入13篇文献，共1380例乳腺癌患者，其中新辅助内分泌组为598例（43.33%），新辅助化疗组为782例（56.67%）。Meta分析结果显示：在ER阳性患者中，两组RR[OR=0.79，95%CI（0.58，1.06），P=0.12]、cCR[OR=0.45，95%CI（0.15，1.39），P=0.16]、pCR[OR=0.56，95%CI（0.28，1.13），P=0.10]、BCS[OR=1.23，95%CI（0.83，1.82），P=0.29]比较，差异无统计学意义（P＞0.05）；在HER-2阴性患者中，两组cCR[OR=0.38，95%CI（0.06，2.33），P=0.30]、pCR[OR=0.56，95%CI（0.24，1.32），P=0.19]比较，差异无统计学意义（P＞0.05）。结论 ER阳性、HER-2阴性的乳腺癌患者行新辅助内分泌治疗可以获得与新辅助化疗相似的疗效，但尚未表现出优势。新辅助内分泌治疗并不能使ER阳性患者得到更多获益。
Abstract:
Objective To systematically evaluate the short-term efficacy of neoadjuvant endocrine therapy and neoadjuvant chemotherapy in breast cancer treatment, with a view to providing a reference for the selection of neoadjuvant treatment methods in clinical diagnosis and treatment.Methods By searching China HowNet, Wanfang, Weipu, China Journal Net full-text database and Cochrane Library, PubMed, EMBASE, Web of Science and other databases, we retrieved the literature that directly compared the short-term efficacy of neoadjuvant endocrine therapy and neoadjuvant chemotherapy, using RevMan 5.3 Meta analysis as a data analysis tool, comparing the tumor remission rate (RR), clinical complete remission rate (cCR), pathological complete remission rate (pCR) and breast-conservation rate (BCS) of the two methods. Results Finally, 13 articles were included, a total of 1380 breast cancer patients, including 598 cases (43.33%) in the neoadjuvant endocrine group and 782 cases (56.67%) in the neoadjuvant chemotherapy group. Meta analysis results showed that: in ER-positive patients, RR [OR=0.79, 95%CI(0.58, 1.06),P=0.12], cCR (OR=0.45,95%CI(0.15,1.39),P=0.16), pCR[OR=0.56, 95%CI(0.28, 1.13), P=0.10], BCS [OR=1.23, 95%CI(0.83, 1.82), P=0.29], the difference was not statistically significant(P＞0.05); In HER-2 negative patients, cCR[OR=0.38, 95%CI(0.06, 2.33), P=0.30], pCR [OR=0.56, 95%CI(0.24, 1.32), P=0.19],the difference was not statistically significant (P＞0.05).Conclusion Neoadjuvant endocrine therapy for breast cancer patients with ER positive and HER-2 negative can obtain similar efficacy as neoadjuvant chemotherapy, but has not shown advantages. Neoadjuvant endocrine therapy does not benefit patients with positive ER.

参考文献/References:

[1]Jemal A,Bray F,Center MM,et al.Global cancer statistics,2012[J].Ca Cancer J Clin,2011,61(2):69-90.[2]Higginson J.International Agency for Research on Cancer[J].Encyclopedia of Toxicology,2014,133(12):1067-1069.[3]张敏璐,黄哲宙,郑莹.中国2008年女性乳腺癌发病、死亡和患病情况的估计及预测[J].中华流行病学杂志,2012,33(10):1049-1051.[4]汪林军,王腾,吴小红,等.血浆微泡乳腺癌耐药蛋白mRNA水平对乳腺癌化疗疗效的预测价值[J].中华实验外科杂志,2015,32(5):976-978.[5]Kaufmann M,von Minckwitz G,Smith R,et al.InternationalExpert Panel on the Use of Primary(Preoperative)Systemic Treatment of Operable Breast Cancer:Review and Recommendations[J].Journal of Clinical Oncology,2003,21(13):2600-2608.[6]Colleoni M,Viale G,Zahrieh D,et al.Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors:A Study of Preoperative Treatment[J].Clinical Cancer Research,2004,10(19):6622-6628.[7]Cortazar P,Zhang L,Untch M,et al.Pathologicalcomplete response and longterm clinical benefifit in breast cancer:the CTNeoBC pooled analysis[J].Lancet,2014,384(9938):164-172.[8]Chollet P,Amat S,Cure H,et al.Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer[J].British Journal of Cancer,2002,86(7):1041-1046.[9]Barroso-Sousa R,Silva DD,Alessi JV,et al.Neoadjuvant endocrine therapy in breast cancer:current role and future perspectives[J].Ecancermedicalscience,2016(10):609.[10]Fontein DB,Charehbili A,Nortier JW,et al.Efficacy of six month neoadjuvant endocrine therapy in postmenopausal,hormone receptor-positive breast cancer patients-A phaseⅡ trial[J].European Journal of Cancer,2014,50(13):2190-2200.[11]Gazet JC,Ford HT,Coombes RC.Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer(a pilot study)[J].British Journal of Cancer,1991,63(2):279-282.[12]Gazet JC,Ford HT,Gray R,et al.Estrogen-receptor-directed neoadjuvant therapy for breast cancer:Results of a randomised trial using formestane and methotrexate,mitozantrone and mitomycin C(MMM)chemotherapy[J].Annals of Oncology,2001,12(5):685-691.[13]Palmieri C,Cleator S,Kilburn LS,et al.NEOCENT:a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer[J].Breast Cancer Res Treat,2014,148(3):581-590.[14]Semiglazov VF,Semiglazov VV,Dashyan GA,et al.Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer[J].Cancer,2007,110(2):244-254.[15]Alba E,Calvo L,Albanell J,et al.Chemotherapy(CT)and hormonotherapy(HT)as neoadjuvant treatment in luminal breast cancer patients:results from the GEICAM/2006-03,a multicenter,randomized,phase-II study[J].Annals of Oncology,2012,23(12):3069-3074.[16]Marcus DM,Switchenko JM,Prabhu R,et al.Neoadjuvant hormonal therapy is associated with comparable outcomes to neoadjuvant chemotherapy in post-menopausal women with estrogen receptor-positive breast cancer[J].Front Oncol,2013,27(3):317.[17]Thomas JSJ,Julian HS,Green RV,et al.Histopathology of breast carcinoma following neoadjuvant systemic therapy:a common association between letrozole therapy and central scarring[J].Histopathology,2007,51(2):219-226.[18]LeVasseur N,Willemsma KA,Li H,et al.Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer:Results From a Prospective Institutional Database[J].Clinical Breast Cancer,2019,19(6):e683-e689.[19]Wright JL,Saigal K,Reis IM,et al.Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+HER2-Breast Cancer[J].American Journal Of Clinical Oncology,2015,40(5):398-411.[20]骆成玉,林华,季晓昕,等.乳腺癌新辅助治疗的临床效果评价[J].北京医学,2007(5):273-275.[21]贾海峰,刘艳艳.绝经后乳腺癌术前新辅助治疗临床应用[J].中国普通外科杂志,2011,20(11):1282-1283.[22]张斌明,盛志娟,姜专基,等.老年乳腺癌新辅助内分泌治疗与新辅助化疗的疗效观察[J].甘肃医药,2016,35(12):907-909.[23]刘战平,刘俊彪.绝经后激素受体阳性乳腺癌新辅助内分泌治疗对比新辅助化疗的非劣性研究[J].临床与病理杂志,2018,38(1):69-73.[24]Cardoso F.Neoadjuvant endocrine therapy:for whom,for how long[J].Clinical and Translational Oncology,2012,14(2):81-82.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
　DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,31(14):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[3]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
　YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,31(14):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[4]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
　LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,31(14):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[5]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,31(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
　ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Medical Information,2018,31(14):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[6]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,31(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
　ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,31(14):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[7]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
　HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,31(14):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[8]阙海涛,曹 斌,秦志刚.EGFL7在乳腺癌中的研究进展[J].医学信息,2018,31(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
　QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Medical Information,2018,31(14):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[9]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,31(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
　ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Medical Information,2018,31(14):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[10]张 乐,徐胜昔,郭翔取,等.Tyrer-Cuzick模型联合SNPs位点在江西地区乳腺癌诊断中应用研究[J].医学信息,2018,31(24):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]
　ZHANG Le,XU Sheng-xi,GUO Xiang-qu,et al.Application of Tyrer-Cuzick Model Combined with SNPs Locus in the Diagnosis of Breast Cancer in Jiangxi Area[J].Medical Information,2018,31(14):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]

更新日期/Last Update: 1900-01-01